Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe

Core Insights - Biomerica, Inc. has received its first commercial order for its Hp Detect™ diagnostic stool antigen test from a major clinical laboratory chain in Europe, specifically for the UK market [1][2][4] - This order signifies a crucial step in the commercialization of Hp Detect™ across Europe, with potential for future distribution discussions in the broader EU market [2][3] - The product's performance has met the rigorous standards of the professional laboratory market, enhancing Biomerica's position for additional distribution relationships in both the US and Europe [3][4] Commercial Significance - The order from a leading clinical laboratory network in Europe is expected to serve as a reference account, facilitating broader adoption of Hp Detect™ in the EU laboratory channel [2][7] - Biomerica anticipates that this initial order will lead to recurring orders as Hp Detect™ becomes integrated into the customer's routine testing workflow [4][7] Market Opportunity - H. pylori is a prevalent bacterial infection, affecting an estimated 45% of the population in Europe's five largest countries, and is recognized as a Class 1 carcinogen by the WHO [4][5][7] - The WHO lists H. pylori among the 16 antibiotic-resistant bacteria that pose significant threats to human health, underscoring the need for accurate diagnostics [4][7] Regulatory Context - Hp Detect™ received registration from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in February 2026, allowing for its commercial use in the UK [1][4] - The National Health Service (NHS) in the UK recommends testing and treating H. pylori in patients with gastrointestinal symptoms, creating a consistent demand for diagnostic products like Hp Detect™ [5][7]